Get started

Chinastocks

Alibaba Shows Oversold ConditionAlibaba is the most prominent of the major Chinese technology stocks that have soared in 2020. It fell sharply after authorities suspended the initial public offering of its Ant finance arm on November 3. That decline has landed BABA deep in oversold territory, according to stochastics. This is the most oversold since June 2019 when Beijing and Washington were clashing over tariffs and trade. BABA has also returned to levels from July and August. The current price area around $260 is near the top of a bullish triangle that the shares escaped in late August (and retested on September 25). Other Chinese tech stocks have kept climbing lately – even as the Nasdaq struggles. At this point there’s a lot of bad news priced into BABA, even though Singles Day set new records. Traders may want to watch for the e-commerce giant to stabilize and start thinking about some kind of bounce. TradeStation is a pioneer in the trading industry, providing access to stocks, options, futures and cryptocurrencies. See our Overview for more.
NYSE:BABA
by TradeStation
1
Baidu Apollo Undervalued (Significantly)1. Baidu have had low valuation due to its stagnant growth of its core business - search engine in China, however, it enjoys a significant moat in this segment as it is the largest market share holder - therefore has network effect. 2. Baidu had been investing significantly in developing AI and autonomous driving over the past few years. Its Apollo project is as good as (if not better), than Google's Waymo. However, Apollo is valued at $1.3 billion only (3% of Baidu's market cap) due to Baidu's core business growth, and unclear roadmap of monetization of Apollo. But, Google's Waymo is valued at $30 billion. It is worth noting that only Waymo and Apollo achieved the L4 auto driving, where they begin 1000+ testing of full self driving on road. Tesla's autonomous driving had been recording data of man's driving, while Waymo and Apollo records data on full self-driving. 3. Recently, Baidu began its robotaxi test drive in Beijing, which received huge responses, had cause the stock price to break out its few months resistance level. Therefore, I believe that the break out from a technical perspective may signify huge support for Baidu in addition to its near term upward trend (typical higher lows). 4. Despite full self driving is still years before it could be full commercialised, Baidu's Apollo had also been providing smart city solutions to assist with provinces of China to solve the traffic issue. In Guangzhou, Baidu received RMB 450 million project. This may be the key monetisation way for Baidu in the next 2-3 years, which is very likely given the traffic issues have been causing waste of resources for China, thus the government is likely invest in smart transportation through Baidu. Therefore, we can expect more projects given by the government, which would be a catalyst moving forward. 5. In mid September, Baidu's management noted that re-listing in Hong Kong would gives it a higher valuation that it currently has. Therefore, we may expect a catalyst from this part. Also, the current risk to reward ratio is worth betting on. If it breaks the current support ( breaking the low of the uptrend), then we might have to look for another entry point. However, recent pull back after break out provide a great entry point.
NASDAQ:BIDULong
by DEHJ
Alibaba Hits New High as Ant IPO ApproachesOne of the more interesting dynamics since the Nasdaq-100 swooned last month has been the relative strength of Chinese technology stocks like Alibaba. This hourly chart compares the Golden Dragon China Index with the Nasdaq-100 . First you have the simple outperformance since the low. Second, notice that HXC made a higher low in late September, while NDX made a lower low . That can indicate Chinese names faced less selling pressure than U.S. megacaps. Alibaba is an important Chinese company. As expected , it probed key support in late September before bouncing. Today it inched to a new all-time high. In contrast, none of the big domestic stocks have returned to old highs since last month’s pullback. For example, TradeStation’s analytics show that the only NDX members to hit new highs in the last week are less prominent firms like Copart , Seattle Genetics and Charter Communications . There are a couple of reasons. One is Ant Group’s initial public offering later this month: The world’s biggest fintech, doing the largest IPO ever – but outside the U.S.! BABA owns one-third of Ant, so could be the main way for Americans to play it. Another reason is China versus the U.S. The Asian country has not only recovered from coronavirus more quickly. It may have less political risk (at least in the near term) than the U.S. Just yesterday, the House of Representatives recommended significant antitrust measures against Apple, Amazon.com , Alphabet and Facebook. While these could prove “more bark than bite” in the long-term, they create uncertainty in the near-term. Maybe that’s why all four of those stocks remain below their 50-day simple moving averages (SMAs) today. Meanwhile, China’s settling into a post-pandemic recovery and seems determined to support its financial markets. TradeStation is a pioneer in the trading industry, providing access to stocks, options, futures and cryptocurrencies. See our Overview for more.
NYSE:BABA
by TradeStation
1
Alibaba May Be Turning Resistance into SupportChinese technology stocks have held their ground better than their U.S. counterparts. The Nasdaq Golden Dragon China Index is 8.5 percent below its 52-week high, while the SPDR Technology Fund is down 12 percent. Alibaba, a key name in the group, has some interesting patterns on its chart. First is the bullish-triangle breakout in August, which it’s now retraced. The previous high around $267 has become the bottom of its range this month. Is old resistance becoming new support? Next, BABA made a slightly lower low on Monday than earlier in September. But it quickly rebounded. That’s a false breakdown and shows that buyers may be willing to defend the support zone. Third is the descending triangle. This may create the potential for a breakout as the downward line converges with the support zone around $267. Still, there could be some near-term chopping and retesting of support. Finally, there may be a catalyst relatively soon. Bloomberg reports that Ant Group wants to raise at least $35 billion in an initial public offering in Hong Kong and Shanghai. (Up from the $30 billion total discussed in August.) BABA owns about one-third of the company. TradeStation is a pioneer in the trading industry, providing access to stocks, options, futures and cryptocurrencies. See our Overview for more.
NYSE:BABA
by TradeStation
$VNET can rise in the next daysContextual immersion trading strategy idea. 21Vianet Group, Inc. provides carrier and cloud-neutral Internet data center services to Internet companies, government entities, blue-chip enterprises, and small-to mid-sized enterprises in the People's Republic of China. The demand for shares of the company still looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $24,14; stop-loss — $23,24. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:VNETLong
by KozakHlib
Chinese Yuan Chart Could Be More Important than the NasdaqThe monster rally in Nasdaq stocks has obviously grabbed most people’s attention recently. However there’s also been a major shift in currency markets as the U.S. dollar slides. That trend has paused for more than a month. Looking simply at the dollar index , it’s not clear whether the decline is ready to continue. But DXY is two-thirds European (euro and sterling). Today we want to look at another currency that’s not even a member of the dollar index: The Chinese Yuan . USDCNY consolidated under roughly 6.85 in the first half of September before breaking lower this week. That was a low in January, so it appears that old support has become resistance. The news flow is also noteworthy because China just reported better-than-expected industrial production. Interestingly, the South China Morning Post ran an editorial yesterday titled “China should seize the moment to free up controls on the yuan to expand its international use.” Coming from an officially sanctioned publication, that seems to indicate Beijing is going to let the yuan appreciate. (Which means USDCNY goes down.) Earlier in the month, Morgan Stanley predicted USDCNY will keep moving toward 6.6 by the end of 2021. Meanwhile, headlines for the U.S. dollar are just the opposite. Our economic data has rebounded somewhat, but more than half the jobs lost to coronavirus remain lost. Meanwhile, Jerome Powell and the Federal Reserve will probably keep the dovishness coming at their meeting tomorrow. Most people probably cannot trade USDCNY. However, gains in the currency have previously lifted Chinese Internet stocks like Alibaba and other members of the Nasdaq Golden Dragon China Index . We entered 2020 expecting money to flow to China after global indexes were changed. Despite the pandemic, that process has been playing out as expected. Could it even accelerate into year end? TradeStation is a pioneer in the trading industry, providing access to stocks, options, futures and cryptocurrencies. See our Overview for more.
by TradeStation
Bullish Charts - Online Learning in ChinaRYB Education, Inc. provides early childhood education service in the People's Republic of China. The company offers kindergarten services to 2-6-year-old children; and play-and-learn centers services for the joint participation of 0-6-year-old children and their adult family members to promote children's development, foster bonding with family, and prepare them for their entry into kindergartens and primary schools. It also develops and sells educational products and services, such as teaching aids, educational toys, at-home educational products, and school uniforms through franchisees and other business partners, as well as directly to a market of families. As of December 31, 2019, it operated 100 directly operated and 250 franchise kindergartens; and 6 play-and-learn centers. The company was formerly known as Top Margin Limited and changed its name to RYB Education, Inc. in June 2017. RYB Education, Inc. was founded in 1998 and is based in Beijing, China. Daily Chart is Bullish Broke out above the cloud yesterday. Indicators are Bullish Long DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
RLong
by HotCharts
2
Baidu: Deep Pullback to Key Support and a Golden CrossChinese stocks have been surging this year as investors embrace the country’s flourishing digital economy. However, one of its most established names hasn’t broken out yet: Baidu – “the Google of China.” BIDU entered the current environment in a weak place after years of revamping its search and advertising business. However it’s reported strong results in the last four quarters. It also surged in June on a report that Tencent may increase its stake in Iqiyi , which is majority owned by BIDU. BIDU has pulled back and digested a lot of its gains in the last two weeks. It’s returned to the $118-120 area where it’s consolidated and pivoted several times in the last year. The stock also just had a “Golden Cross,” with the 50-day simple moving average (SMA) rising up and through the 200-day SMA. This can reflect a long-term change in momentum – potentially interesting in a stock that’s lost more than half its value since July 2018.
NASDAQ:BIDULong
by TradeStation
Moderna in Trouble - ABUS Wins Lawsuit Tied to COVID-19 DrugArbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-836, a capsid inhibitor that has the potential to inhibit HBV replication by preventing the assembly of functional viral capsids; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. In addition, it develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer, an orally active agent that cause the destabilization of HBV RNAs, which leads to RNA degradation and to reduction in HBsAg levels. Further, the company engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with standard of care therapies, and in combination with each other. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania. AFTER HOURS BREAKING NEWS Moderna stock tumbled late Thursday after the biotech lost a patent battle that may jeopardize the financial future of its coronavirus vaccine. Moderna (MRNA) challenged patents held by Arbutus Biopharma (ABUS) covering lipid nanoparticle, or LNP, technology. Lipid nanoparticles are the delivery system for messenger RNA drugs, including Moderna's coronavirus vaccine, which is known as mRNA-1273. Despite the company's contention, the ruling could cut into profits on any Moderna drug, including mRNA-1273, says SVB Leerink analyst Mani Foroohar. "Revenue concentration in (the coronavirus vaccine) is a central feature of the investment case for Moderna shares," Foroohar said. "Any meaningful royalty burden could hamper Moderna's pricing flexibility and margin profile vs. other players in the SARS-CoV-2 vaccine market." Foroohar called the decision in Arbutus' favor "a disappointing turn for Moderna." "This decision opens the door to a fascinating (and likely protracted) period of investor controversy and debate around the implications of any potential infringement of claims by Arbutus regarding Moderna's use of Lipid Nanoparticle delivery technology, and any further actions Moderna may take to defend their own (intellectual property) position and freedom to operate," he said. NEWS: www.investors.com Where's ABUS going? To $100.00 ...??? On the monthly chart, it looks like $9.00 might be the next stop..? At this point, I am not sure if there is a top right now for ABUS. The news is huge for ABUS and could entitle ABUS to billions in profits and revenue from the COVID-19 vaccine. Intelligent comments welcome. DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:ABUSLong
by HotCharts
4
Timeline: NIO vs. TSLA = NIO Target $350 to $500Don't shoot the messenger! I have a timeline of Tesla below which should put a price target on NIO North of $400 to $500 a share. www.thestreet.com As we stand today, NIO is much more successful than Tesla ever was and at this time, or there a bouts, compared to Tesla at or around the same time period in production & sales, Tesla was trading north of $360 a share and only delivered 2,400 cars compared to NIO delivering over 46,000 vehicles. "Entering 2018 Tesla faced several difficulties. Missed predictions had led investors to dump the company's stock, and in the middle of 2017 it lost more than 5% of its value in a collapse worth $12 billion. By January, 2018 Tesla was producing its Model 3 sedans at a fraction of the rate it had anticipated. Over a three-month period the company managed to finish and ship 2,400 cars after promising consumers and investors that it could complete more than 5,000 per week." On 07/02/2020, NIO announced as of June 30, NIO delivered 46,082 vehicles with 14,169 already delivered for 2020. These sales figures topple what Tesla sold and at or around the same time period, Tesla stock spiked to around $389.61. These are real figures from the Tesla timeline I have listed herein and using monthly stock charts for Tesla's stock price at that time period. NIO is also in much better financial condition than Tesla ever was at or around the same time in the production and sales cycle / timeline. Folks, when you look at the monthly stock prices for Tesla, and compare the timeline link I have herein, NIO is extremely cheap and deeply undervalued at current levels. Also, NIO has the Chinese Government behind them. Tesla, at or around when the company started, only raised $500 million from a DOE loan and Tesla was burning cash like water. NIO just raised almost $1 Billion in funding. NIO is financially in a better place than what Tesla ever was. The way I see it, the Chinese Government will not let NIO fail to Tesla, a USA auto company. In my opinion, after researching Tesla vs. NIO, I personally think NIO should be trading at or around $350 to $500 a share with their financial and sales figures. Best of luck longs! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NYSE:NIOLong
by HotCharts
12